 |
Top 9 Cancer treatment startups in Israel
Oct 02, 2025 | By Jason Kwon | 29 |
1
Funding: $1B
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
2
Funding: $118.5M
Ibex is pioneering AI-based cancer diagnostics in pathology. Its Galen platform uses AI-based algorithms to analyze images, detect and grade cancer in biopsies, helping pathologists reduce diagnostic error rates and enable a more efficient workflow.
Ibex is pioneering AI-based cancer diagnostics in pathology. Its Galen platform uses AI-based algorithms to analyze images, detect and grade cancer in biopsies, helping pathologists reduce diagnostic error rates and enable a more efficient workflow.
3
Funding: $101.5M
KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
4
Funding: $72M
Ayala Pharmaceuticals develops a personalized treatment for cancer.
Ayala Pharmaceuticals develops a personalized treatment for cancer.
5
Funding: $65M
NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.
NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.
6
Funding: $60.5M
Nucleai aims to Improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better by using Machine Learning, Deep Learning, and Machine Vision technology.
Nucleai aims to Improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better by using Machine Learning, Deep Learning, and Machine Vision technology.
7
Funding: $59M
BioSight is a biopharmaceutical company revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
BioSight is a biopharmaceutical company revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
8
Funding: $52.6M
OncoHost is developing cutting-edge technology to characterize, analyze, and predict patient response to treatment, enabling personalized treatment strategies with improved outcomes & reduced side effects.
OncoHost is developing cutting-edge technology to characterize, analyze, and predict patient response to treatment, enabling personalized treatment strategies with improved outcomes & reduced side effects.
9
Funding: $21.5M
Our mission is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from H&E image. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.
Our mission is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from H&E image. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.
★
See also:
